Back

Substrate characterization and outcomes of ventricular tachycardia ablation in amyloid cardiomyopathy: a worldwide study

8 April 2024 (11:10 - 11:19)
Organised by: Logo
Congress Presentation Part of: Ventricular tachycardia: ablation Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Paolo Compagnucci

University Hospital Riuniti of Ancona, Ancona (Italy)

6 More presentations in this session

Presentation thumbnail
Cardiac magnetic resonance to evaluate 3D ventricular substrate depth: Prognostic implications for VT ablation approach
Doctor S. Vazquez-Calvo (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Impact of functional gene groups on outcomes after ablation of ventricular tachycardia in patients with inherited left ventricular cardiomyopathy: an international multicentre study
Doctor Y. Kimura (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
First experience of focal pulsed field ablation for premature ventricular contractions
Doctor M. Cespon Fernandez (Vigo, ES)
Abstract Slides Video
Presentation thumbnail
Identification of reentry vulnerable targets during substrate mapping for ablation in scar related VT: the "visual" reentry vulnerability index
Doctor J. Tonko (London, GB)
Abstract Slides Video
Presentation thumbnail
Neural network for automatic ICD-EGMs matching in pace-mapping and ablation of ventricular arrhythmias.
Doctor E. Lian (Kiel, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular tachycardia: ablation
Video

The Event

Event poster

EHRA 2024

8 April 2024 11:10 CET
You may be interested in
thumbnail
Congress Presentation
Management of arrhythmias in cardiac amyloidosis
thumbnail
Congress Presentation
Reduced heart failure hospitalizations and improved quality of life in cardiac amyloidosis patients undergoing atrial fibrillation ablation
thumbnail
Congress Presentation
Catheter ablation for atrial fibrillation in patients with cardiac amyloidosis - Clinical characteristics and outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources